Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10504 Combination Therapy in Advanced NSCLC
NCT07414953Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2026
- Primary completion
- Apr 2027
01
Overview
Phase 1, open-label trial of HS-10504 in non-small cell lung cancer (NSCLC) (5 cohorts), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Recommended Phase 2 Dose at 2 years, Objective Response Rate at 2 years and 3 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
HS-10504
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07414953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07414953.